Advertisement
Review Article| Volume 32, ISSUE 1, P143-151, January 2023

Surgeon-Led Clinical Trials in Pancreatic Cancer

  • Akhil Chawla
    Affiliations
    Division of Surgical Oncology, Department of Surgery, Northwestern Medicine Regional Medical Group, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 650Chicago, IL 60611, USA

    Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Search for articles by this author
  • Cristina R. Ferrone
    Correspondence
    Corresponding author. Wang 460, 15 Parkman Street, Boston, MA 02114.
    Affiliations
    Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
    Search for articles by this author
Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.08.001
Surgeon-Led Clinical Trials in Pancreatic Cancer
Previous ArticleColorectal Cancer Liver Metastases
Next ArticlePrimary Colorectal Cancer

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703https://doi.org/10.1056/NEJMoa1304369
        View in Article
        • Conroy T.
        • Paillot B.
        • François E.
        • et al.
        Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
        J Clin Oncol. 2005; 23: 1228-1236https://doi.org/10.1200/JCO.2005.06.050
        View in Article
        • Oettle H.
        • Neuhaus P.
        • Hochhaus A.
        • et al.
        Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
        JAMA. 2013; 310: 1473-1481https://doi.org/10.1001/jama.2013.279201
        View in Article
        • Neoptolemos J.P.
        • Stocken D.D.
        • Friess H.
        • et al.
        A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med.
        . 2004; 350: 1200-1210https://doi.org/10.1056/NEJMoa032295
        View in Article
        • Maeda A.
        • Boku N.
        • Fukutomi A.
        • et al.
        Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
        Jpn J Clin Oncol. 2008; 38: 227-229https://doi.org/10.1093/jjco/hym178
        View in Article
        • Neoptolemos J.P.
        • Palmer D.H.
        • Ghaneh P.
        • et al.
        Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
        Lancet. 2017; 389: 1011-1024https://doi.org/10.1016/s0140-6736(16)32409-6
        View in Article
        • Murphy J.E.
        • Wo J.Y.
        • Ryan D.P.
        • et al.
        Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
        JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.0329
        View in Article
        • Murphy J.E.
        • Wo J.Y.
        • Ryan D.P.
        • et al.
        Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
        JAMA Oncol. 2019; https://doi.org/10.1001/jamaoncol.2019.0892
        View in Article
        • Katz M.H.
        • Shi Q.
        • Ahmad S.A.
        • et al.
        Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
        JAMA Surg. 2016; 151: e161137https://doi.org/10.1001/jamasurg.2016.1137
        View in Article
        • Jang J.Y.
        • Han Y.
        • Lee H.
        • et al.
        Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
        Ann Surg. 2018; 268: 215-222https://doi.org/10.1097/sla.0000000000002705
        View in Article
        • Tempero M.A.
        • Reni M.
        • Riess H.
        • et al.
        APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
        J Clin Oncol. 2019; 37: 4000https://doi.org/10.1200/JCO.2019.37.15_suppl.4000
        View in Article
        • Tempero M.
        • O'Reilly E.
        • Van Cutsem E.
        • et al.
        LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival.
        Ann Oncol. 2021; 32: S226https://doi.org/10.1016/j.annonc.2021.06.009
        View in Article
        • Conroy T.
        • Hammel P.
        • Hebbar M.
        • et al.
        FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
        N Engl J Med. 2018; 379: 2395-2406https://doi.org/10.1056/NEJMoa1809775
        View in Article
        • Conroy T.
        • Hammel P.
        • Turpin A.
        • et al.
        LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC).
        Ann Oncol. 2021; 32: S1334https://doi.org/10.1016/j.annonc.2021.08.2137
        View in Article
        • Hsu C.C.
        • Herman J.M.
        • Corsini M.M.
        • et al.
        Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
        Ann Surg Oncol. 2010; 17: 981-990https://doi.org/10.1245/s10434-009-0743-7
        View in Article
        • Sohal D.
        • Duong M.T.
        • Ahmad S.A.
        • et al.
        SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).
        J Clin Oncol. 2020; 38: 4504https://doi.org/10.1200/JCO.2020.38.15_suppl.4504
        View in Article
        • Chawla A.
        • Ferrone C.R.
        Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift.
        Front Oncol. 2019; 9: 1085https://doi.org/10.3389/fonc.2019.01085
        View in Article
        • Unno M.
        • Motoi F.
        • Matsuyama Y.
        • et al.
        Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
        J Clin Oncol. 2019; 37: 189https://doi.org/10.1200/JCO.2019.37.4_suppl.189
        View in Article
        • de Bono J.S.
        • Twelves C.J.
        The oral fluorinated pyrimidines.
        Invest New Drugs. 2001; 19: 41-59https://doi.org/10.1023/a:1006404701008
        View in Article
        • Satoi S.
        • Unno M.
        • Motoi F.
        • et al.
        The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).
        J Clin Oncol. 2019; 37: 4126https://doi.org/10.1200/JCO.2019.37.15_suppl.4126
        View in Article
        • Katz M.H.
        • Marsh R.
        • Herman J.M.
        • et al.
        Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
        Ann Surg Oncol. 2013; 20: 2787-2795https://doi.org/10.1245/s10434-013-2886-9
        View in Article
      22. NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma Version 1.2022. National Comprehensive Cancer Network.
        (Available at:)
        https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
        (Accessed 05/01/2022)
        View in Article
        • Ahmad S.A.
        • Duong M.
        • Sohal D.P.S.
        • et al.
        Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
        Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000004155
        View in Article
        • de W Marsh R.
        • Talamonti M.S.
        • Baker M.S.
        • et al.
        Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.
        J Surg Oncol. 2018; 117: 354-362https://doi.org/10.1002/jso.24872
        View in Article
        • Versteijne E.
        • Suker M.
        • Groothuis K.
        • et al.
        Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
        J Clin Oncol. 2020; 38: 1763-1773https://doi.org/10.1200/jco.19.02274
        View in Article
        • Kunzmann V.
        • Siveke J.T.
        • Algül H.
        • et al.
        Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
        Lancet Gastroenterol Hepatol. 2021; 6: 128-138https://doi.org/10.1016/S2468-1253(20)30330-7
        View in Article
        • Chawla A.
        • Qadan M.
        • Castillo C.F.
        • et al.
        Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.
        Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000004585
        View in Article

      Article info

      Publication history

      Published online: November 03, 2022

      Identification

      DOI: https://doi.org/10.1016/j.soc.2022.08.001

      Copyright

      © 2022 Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX